Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

The U.S. eliminated measles 26 years ago. Now it could lose that status in a matter of weeks

The U.S. declared measles eliminated in 2000—but it could soon lose that status, depending on the conclusions of a meeting of the Pan American Health Organization (PAHO) next month. Measles cases in the United States are rising; there could be twice as many cases in 2026 as in 2025. The measles tracker run by John Hopkins Bloomberg School of Public Health counted 4,267 cases as of October 15. The…

The U.S. eliminated measles 26 years ago. Now it could lose that status in a matter of weeks

In 2000, the United States declared measles eliminated, but that status could be lost in the near future. Recent data from the John Hopkins Bloomberg School of Public Health shows a surge in cases, with 4,267 reported as of October 15, nearly double the 2,286 cases from the previous year. Pennsylvania has seen over 1,000 cases, while South Carolina and Utah follow with significant totals as well.

The CDC defines measles elimination as a year-long period with no continuous spread within a defined geographical area. However, since late 2023, the U.S. has witnessed ongoing transmission. Experts highlight that 97% of this year's cases are in unvaccinated individuals, indicating a weakened public health system. The Pan American Health Organization (PAHO), responsible for reviewing the U.S.'s elimination status, initially scheduled a meeting for April but delayed it to November due to simplification and additional data analysis time.

This decision has raised concerns about the U.S.'s ability to maintain measles elimination. The U.S. Department of Health and Human Services, along with the CDC, has increased funding for measles preparedness, emphasizing the importance of the MMR vaccine. However, the U.S. still faces challenges in achieving the 95% immunity coverage required to prevent outbreaks.

The upcoming PAHO meeting on November 10-13 will assess the re-establishment of endemic measles transmission, providing a critical opportunity to evaluate the country's public health progress.

Written by urgent.news from Fast Company's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at fastcompany.com →

More in Health & Medicine

The FDA Must End Unnecessary Drug Trials | Opinion

The Food and Drug Administration should cut biosimilar trials to reduce costs, boost competition and improve patient access.

  • FDA drafts recommendations to streamline PK testing, potentially saving 50% costs.
  • Comparative efficacy studies may be redundant with other evidence establishing biosimilarity.
  • Regulators must adopt evidence-based guidelines excluding routine trials for biosimilars.

More from Friday 16 October →